Erika Hamilton, MD
Basic profileDirector of Breast Cancer Research Program and Chair of Executive Breast Cancer Research Committee, Sarah Cannon Research Institute · Sarah Cannon
Erika Hamilton is Director of Breast Cancer Research Program and Chair of Executive Breast Cancer Research Committee, Sarah Cannon Research Institute at Sarah Cannon. OpenAlex indexes 847 publications with 19,105 citations (h-index 61); ClinicalTrials.gov lists 8 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Updated 18 Oct 2026
Erika Hamilton, M.D., is Director of Breast Cancer Research Program and Chair of Executive Breast Cancer Research Committee, Sarah Cannon Research Institute. The public record shows 847 publications with 19,198 citations (h-index 61), centered on Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 66 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Advanced Breast Cancer Therapies
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 66 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 242.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
250 25th Ave N
Suite 100
Nashville, TN 37203-1632
Telephone
615-320-5090Registry record last updated 19 Aug 2013 · collected 28 Jul 2026.
Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
Industry payments
Updated 18 Oct 2026
66 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202520 payments$16,250openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20259 payments$11,432openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
73%RANK Ligand Inhibitor73%Denosumab100%Part B, office-administered≥13 patientsSensory organs
22.7%Corticosteroid22.7%Dexamethasone sodium phosphate100%Part B, office-administered≥23 patientsCancer & immunology
3%Aromatase Inhibitor2.1%Letrozole100%Part D≥28 patientsEstrogen Agonist/Antagonist0.9%Tamoxifen Citrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Congress activity
Updated 18 Oct 2026
364 congress contributions (2009–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract CT045: Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancer
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Journal of clinical oncology
Clinical Trial2026 - DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.
Clinical cancer research
Clinical Trial2026 - A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.
Clinical cancer research
Clinical Trial2026 - Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerArticle1,322 citations2019
- 02Targeting HER2-positive breast cancer: advances and future directionsReview1,138 citations2022
- 03
- 04HER2-Low Breast Cancer: Pathological and Clinical LandscapeArticle794 citations2020
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- BSc in Neuroscience
Washington and Lee University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗ - MD
University of North Carolina at Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗ - Fellowship in Oncology
Duke University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emjreviews.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
- Cancer Research Committee Member
American Society of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗ - Associate Editor
Clinical Breast Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗ - Board Member
Susan G. Komen Foundation of Central Tennessee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Scientific Committee Member
American Association for Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Awards & honors
honors on the public record- Fellow
American Society of Clinical Oncology (FASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →infoaj7.podbean.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →contemporaryobgyn.net ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →backtable.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scri.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Denise Aysel Yardley
Sarah Cannon
Meredith McKean, MD
Sarah Cannon
Meredith Pelster, MD
Sarah Cannon
Mythili Shastry
Sarah Cannon
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”